Company profile: WuXi Advanced Therapies
1.1 - Company Overview
Company description
- Provider of CDMO and integrated laboratory testing services to accelerate bio-based drugs, including TESSA scalable AAV vector production; XOFLX packaging and producer cell lines for lentiviral vectors; process development, IND-enabling studies, and phase-appropriate clinical manufacturing; plus comprehensive testing (viral clearance, biosafety, release, cell banking, stability) for cell and gene therapies, monoclonal antibodies, and vaccines.
Products and services
- Clinical Manufacturing: Phase-appropriate, CDMO-operated manufacturing that accelerates timelines and ensures quality clinical production for advanced therapies by leveraging integrated platforms and laboratory testing
- Process Development: GMP-ready services that develop, scale, and optimize processes and methods for cell and gene therapies, ensuring GMP readiness
- Contract Testing Services: Multi-assay laboratory platforms delivering viral clearance, biosafety, release testing, cell banking, and stability for cell and gene therapies, monoclonal antibodies, and vaccines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to WuXi Advanced Therapies
Biomind Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical development for neurological and psychiatric disorders, advancing candidates including BMND01 for treatment-resistant depression, BMND03 for addictive disorders, BMND07 for major depressive disorder, BMND09 for Parkinson’s disease, BMND08 for depression and anxiety in Alzheimer’s disease, and Triptax™, a new chemical entity for treatment-resistant depression with FDA IND clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomind Labs company profile →
Anagram
HQ: Spain
Website
- Description: Provider of clinical research organization (CRO) services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anagram company profile →
ICON
HQ: Ireland
Website
- Description: Provider of outsourced development services to pharmaceutical, biotechnology, medical device, biosimilar and generic organizations, specializing in strategic development, management and analysis of programs supporting clinical development from compound selection through Phase I-IV clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ICON company profile →
Integrity Bio
HQ: United States
Website
- Description: Provider of contract development and manufacturing services focused on biologics formulation and GMP fill-finish. Offers formulation, process development, clinical and commercial production; cGMP analytical testing (chromatography, mass spectrometry, NMR); batch release and stability testing; separation science; analytical method development/validation; consultative services. Specializes in hard-to-formulate liquid and lyophilized products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Integrity Bio company profile →
EirGen Pharma
HQ: Ireland
Website
- Description: Provider of high potency oral solid dose medicines for human and veterinary use and contract development, manufacturing, and packaging services for the global pharmaceutical market, including research, formulation, and analytical development and investigational medicinal products. Fully licensed to manufacture oncology, cytotoxic, steroidal, and immunosuppressant molecules in purpose-built high containment suites, covering film-coated tablets, soft-gel, and hard-shell capsules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EirGen Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for WuXi Advanced Therapies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to WuXi Advanced Therapies
2.2 - Growth funds investing in similar companies to WuXi Advanced Therapies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for WuXi Advanced Therapies
4.2 - Public trading comparable groups for WuXi Advanced Therapies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →